Journal
JOURNAL OF CLINICAL GASTROENTEROLOGY
Volume 55, Issue 8, Pages 702-708Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MCG.0000000000001416
Keywords
inflammatory bowel disease; ulcerative colitis; curcumin; clinical trial; phytochemical
Categories
Ask authors/readers for more resources
The study demonstrates that BEC is effective in inducing clinical and endoscopic remission in patients with mild-to-moderately active UC on mesalamine therapy, with sustained remission and high safety profile.
Background and Aims: The aim of this study was to assess the efficacy and safety of a novel, hydrophilic, bioenhanced curcumin (BEC) as add-on therapy in inducing clinical and endoscopic remission in mild to moderately active ulcerative colitis (UC). Design: Mild to moderately active UC patients (partial Mayo score 2 to 6 with endoscopic Mayo score >1) on standard dose of mesalamine were randomized to either 50 mg twice daily BEC or an identical placebo. Clinical response (>= 2 reduction of partial Mayo score), clinical remission (partial Mayo score <= 1), and endoscopic remission (endoscopic Mayo score of <= 1) were evaluated at 6 weeks and 3 months. Responders were followed-up at 6 and 12 months for assessing maintenance of remission. Results: Sixty-nine patients were randomly assigned to BEC (n=34) and placebo (n=35). At 6 weeks, clinical and endoscopic remission occurred in 44.1% (15/34) and 35.3% (14/34) patients, respectively, compared with none in the placebo group (P<0.01). Clinical response was also significantly higher in the BEC group (18/34, 52.9%) compared with placebo (5/35, 14.3%) (P=0.001). The clinical remission, clinical response, and endoscopic remission rates at 3 months were 55.9% (19/34), 58.8% (20/34), 44% (16/34) and 5.7% (2/35), 28.6% (10/35), 5.7% (2/35) in BEC and placebo groups, respectively. At 6 and 12 months, 95% (18/19) and 84% (16/19) of the responders to BEC maintained clinical remission. None of the responders to placebo maintained clinical remission at 6 months. BEC appeared safe with no significant side effects. Conclusion: A low-dose BEC as add-on therapy was superior to placebo in inducing sustained clinical and endoscopic remission in patients with mild-to-moderately active UC on maximal dose of mesalamine (ClinicalTrials.gov: NCT02683733).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available